etanercept
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Inflammation
Conditions
Inflammation, Psoriasis
Trial Timeline
Oct 1, 2004 → —
NCT ID
NCT00121615About etanercept
etanercept is a phase 3 stage product being developed by Amgen for Inflammation. The current trial status is completed. This product is registered under clinical trial identifier NCT00121615. Target conditions include Inflammation, Psoriasis.
What happened to similar drugs?
2 of 14 similar drugs in Inflammation were approved
Approved (2) Terminated (2) Active (10)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00111111 | Phase 3 | Completed |
| NCT05135312 | Approved | UNKNOWN |
| NCT02749370 | Approved | Completed |
| NCT02274792 | Approved | Completed |
| NCT01971346 | Approved | Completed |
| NCT01543204 | Approved | Terminated |
| NCT01132235 | Approved | UNKNOWN |
| NCT01009879 | Approved | Withdrawn |
| NCT00833729 | Approved | Completed |
| NCT00640393 | Approved | Completed |
| NCT01053819 | Approved | Completed |
| NCT00477191 | Pre-clinical | Terminated |
| NCT00585650 | Phase 1/2 | Completed |
| NCT00413452 | Phase 3 | Completed |
| NCT00361634 | Phase 1 | Completed |
| NCT00333034 | Phase 3 | Completed |
| NCT00322439 | Pre-clinical | Completed |
| NCT00332332 | Approved | Completed |
| NCT00346294 | Approved | Completed |
| NCT00965666 | Phase 1 | Completed |
Competing Products
20 competing products in Inflammation